loader2
Login Open ICICI 3-in-1 Account
  • Text Size
  • Text to Speech
  • Color Contrast
  • Pause Animations
Open ICICI 3-in-1 Account

Emcure Pharmaceuticals Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Emcure Pharmaceuticals Ltd. 06 Aug 2026 14:29 PM
Result PDF

Q1FY27 Quarterly Result Announced for Emcure Pharmaceuticals Ltd.

Pharmaceuticals company Emcure Pharmaceuticals announced Q1FY27 results

Consolidated Financial Highlights:

  • Revenue from Operations: The company reported revenue of Rs 25,804.47 million in Q1FY27, representing a growth of 22.84% compared to Rs 21,005.37 million in Q1FY26 (YoY) and an increase of 4.48% from Rs 24,697.03 million in Q4FY26 (QoQ).
  • Total Income: Total income for the quarter stood at Rs 25,825.18 million, up 22.73% YoY from Rs 21,042.33 million and up 4.40% QoQ from Rs 24,736.95 million.
  • EBITDA: Consolidated EBITDA stood at Rs 5,080 million in Q1FY27, registering a growth of 25.80% YoY from Rs 4,039 million and a growth of 4.63% QoQ from Rs 4,855 million.
  • EBITDA Margin: The EBITDA margin improved to 19.7% in Q1FY27 compared to 19.2% in Q1FY26 and remained stable at 19.7% compared to Q4FY26.
  • Profit Before Tax (PBT): PBT (before exceptional items) was Rs 3,935.26 million in Q1FY27, an increase of 33.74% from Rs 2,942.58 million in Q1FY26 and up 18.93% from Rs 3,308.75 million in Q4FY26.
  • Net Profit: Net profit for the period reached Rs 2,924.93 million in Q1FY27, reflecting a growth of 36.17% YoY from Rs 2,147.93 million and a 20.00% increase QoQ from Rs 2,437.36 million.
  • Earnings Per Share (EPS): Basic and Diluted EPS stood at Rs 15.50 for Q1FY27, compared to Rs 10.92 in Q1FY26 and Rs 12.84 in Q4FY26.

Standalone Financial Highlights:

  • Revenue from Operations: Standalone revenue for Q1FY27 was Rs 14,509.31 million, a growth of 32.31% YoY from Rs 10,965.73 million and a marginal decline of 1.14% QoQ from Rs 14,677.03 million.
  • Total Income: Total standalone income stood at Rs 14,759.63 million in Q1FY27, up 32.01% YoY from Rs 11,180.97 million.
  • Net Profit: Standalone PAT reached Rs 2,001.08 million in Q1FY27, representing a YoY growth of 63.0% from Rs 1,227.89 million and a QoQ decline of 14.37% from Rs 2,336.97 million.

Business Highlights

  • Segment Performance: The group operates primarily in a single reportable segment, "Pharmaceuticals".
  • Domestic Business: Revenue from the domestic market grew by 10.2% YoY to Rs 10,953 million, accounting for 42.4% of consolidated revenue. Growth was driven by brands in CNS, cardiology, and the women’s health franchise.
  • International Business: International sales stood at Rs 14,851 million, showing a robust growth of 34.2% YoY and contributing 57.6% to consolidated revenue.
    • Europe: Grew by 32.8% YoY to Rs 5,367 million.
    • Canada: Grew by 24.6% YoY to Rs 4,266 million.
    • Rest of World (RoW): Grew by 44.8% YoY to Rs 5,218 million, led by ARV performance.
  • Research & Development: R&D investment stood at Rs 904 million, representing 3.5% of the total revenue for the quarter.
  • Operational Updates:
    • Acquired 100% of Cutimed Inc. in Canada effective April 1, 2026, to strengthen the dermatology and cosmetic portfolio.
    • Acquired the remaining minority stake in Gennova Biopharmaceuticals, making it a wholly-owned subsidiary effective July 21, 2026.
    • Gennova executed a Business Transfer Agreement (BTA) for the slump sale of its mRNA business for Rs 1,395 million on July 10, 2026.
  • Leadership Changes: Mr. Berjis Desai will retire as Chairman. Post the upcoming AGM, Mr. Satish Mehta will take over as Chairman in addition to his role as Managing Director and CEO. Mr. Samit Mehta has been appointed as the Chief Operating Officer of Emcure and CEO of Gennova.
  • Management Commentary (Verbatim)

Satish Mehta, Managing Director and CEO, Emcure Pharmaceuticals, said: "We have begun FY27, the second year of our five-year plan—on a strong footing. FY26 was about putting the building blocks in place across teams, portfolio, integration and operating discipline. FY27 is about delivery, and Q1 is an encouraging early signal.

Revenue grew 22.8% year-on-year to Rs 25,804 million and was supported by momentum across geographies. EBITDA grew 25.8% to Rs 5,080 million with margin improving to 19.7%, up ~50 basis points year-on-year, reflecting productivity gains and operating leverage. PAT grew faster at 36.2% to Rs 2,925 million, underlining the strength of the quarter's operating performance."

Result PDF

Result PDF

Pharmaceuticals company Emcure Pharmaceuticals announced Q4FY26 & FY26 results

Q4FY26 Financial Highlights:

  • Revenue from operations at Rs 2,470 crore, up 16.7% YoY.
  • EBITDA at Rs 485 crore up 24.5% YoY, EBITDA margins at 19.7%.
  • Reported PAT at Rs 244 crore, up 23.6% YoY.
  • Adj. PAT2 at Rs 279 crore, up by 36.0% YoY.
  • Domestic business sales at Rs 977 crore, up 5.2% YoY. Softer performance largely due to the Zuventus portfolio and team reorganization.
  • International business sales at Rs 1,493 crore, up 25.7% YoY with strong growth across markets supported by base business ramp up and new launches.

FY26 Financial Highlights:

  • Revenue from operations at Rs 9,204 crore, up 16.6% YoY, ahead of stated guidance.
  • EBITDA at Rs 1,789 crore up 21.8% YoY, EBITDA margins at 19.4%.
  • Reported PAT at Rs 941 crore, up 33.1% YoY.
  • Adj. PAT2 at Rs 1,008 crore, up by 40.9% YoY.
  • Domestic business sales at Rs 4,027 crore, up 10.0% YoY. Growth in-line with market, led by cardiac, CNS and oncology. Consolidated domestic operations with subsidiary minority stake buyout, strengthened leadership teams across divisions and expanded portfolio via key MNC partnerships.
  • International business sales at Rs 5,177 crore, up 22.2% YoY. Strong momentum from base business growth and new launches from in-house portfolio.

Satish Mehta, CEO & Managing Director, Emcure Pharmaceuticals, said: "In FY26, the first year of our five-year strategic plan, Emcure delivered strong financial performance with over USD 1 billion in revenue and 16.6% growth. International markets demonstrated robust momentum while our domestic business recorded steady growth. We delivered ~41% adjusted PAT growth in the year. We strategically expanded through in-licensing, Zuventus minority buyout and bolt-on acquisitions in the UK and Canada. Our R&D pipeline in complex injectables and biosimilars remains a key driver of future value. Our priorities remain clear - to deliver sustainable, above-industry growth and consistent margin expansion, while continuing to build sustainable long-term value for all stakeholders.”

Result PDF

Pharmaceuticals company Emcure Pharmaceuticals announced Q3FY26 results

  • Revenue from operations at Rs 2,363 crore, up 20.4% YoY.
  • EBITDA margins at 19.5% with EBITDA at Rs 460 crore up 27.2% YoY.
  • PAT at Rs 231 crore, up 48.2% YoY.
  • PAT includes Exceptional expense of Rs 38 crore related to labour code changes.
  • Domestic business sales at Rs 1,025 crore, up 15.4% YoY.
  • International business sales at Rs 1,338 crore, up 24.5% YoY.

Satish Mehta, CEO & Managing Director, Emcure Pharmaceuticals, said: “Q3 delivered a strong performance, with all our businesses outpacing industry growth. During the period, we strengthened our India portfolio with launch of Poviztra®, a biological injectable semaglutide. Our international business continues to see strong growth led by launch of our differentiated product pipeline. Emcure’s focus remains on improving profitability even as we invest in people, products and processes to drive strong growth.

We continue to augment our portfolio in all our focus markets though in-house R&D and in-licensing. The Novo Nordisk partnership has given Emcure an early-entry advantage, positioning us well in the fast-growing obesity segment. We remain focused on delivering strong growth along with margin improvement.”

Result PDF

Pharmaceuticals company Emcure Pharmaceuticals announced Q2FY26 results

  • Revenue from operations at Rs 2,270 crore, up 13.4% YoY.
  • EBITDA margins at 19.3% with EBITDA at Rs 439 crore up 15.2% YoY.
  • PAT at Rs 251 crore, up 24.7% YoY.
  • Domestic business sales at Rs 1,031 crore, up 10.6% YoY.
  • International business sales at Rs 1,238 crore, up 15.8% YoY.

Satish Mehta, CEO & Managing Director, Emcure Pharmaceuticals, said: “Q2 saw strong performance across all our businesses. We continue to augment our portfolio in all our focus markets though in-licensing and inhouse developments. Novo Nordisk partnership positions us well in the fast-growing obesity segment and gives us an early entry enabling us to shape the market. We remained focus on delivering strong growth along with margin improvement in all our key businesses.”

Result PDF

Pharmaceuticals company Emcure Pharmaceuticals announced Q1FY26 results

  • Revenue from operations at Rs 2,101 crore, up 15.7% YoY.
  • EBITDA margins at 19.2% with EBITDA up 20.1% YoY.
  • PAT at Rs 215 crore, up 41% YoY.
  • Domestic business sales at Rs 995 crore, up 9.4% YoY.
  • International business sales at Rs 1,106 crore, up 22.1% YoY.

Satish Mehta, CEO & Managing Director, Emcure Pharmaceuticals, said: “We delivered robust performance across all businesses in Q1. We continue to augment our portfolio in all our focus markets though in-licensing and in-house development. The expanded Sanofi partnership positions us well in the fast growing metabolic segment. We also have a strong product pipeline for both our domestic and international markets which will fuel future growth. We remain focused on improving efficiencies to drive sustained improvement in margins. ”

Result PDF

Pharmaceuticals company Emcure Pharmaceuticals announced Q4FY25 & FY25 results

Q4FY25 Financial Highlights:

  • Revenue from operations at Rs 2,116 crore, up 19.5% YoY
  • EBITDA margins at 18.4% with EBITDA up 25.2% YoY
  • PAT at 197 crore, up 63.0% YoY
  • Domestic business sales at 929 crore, up 24.8% YoY
  • International business sales at 1,187 crore, up 15.6% YoY
  • The Board has proposed a final dividend of Rs 3/- per share

FY25 Financial Highlights:

  • Revenue from Operations stood at Rs 7,896 crore for FY25 compared to Rs 6,658 crore FY24 up 18.6%
  • EBITDA stood at Rs 1,469 crore for FY25 compared to Rs 1,230 crore for FY24 up 19.4%
  • PAT at Rs 707 crore for FY25 compared to Rs 528 crore for FY24 up 34.1%

Commenting on the results, Satish Mehta, CEO and Managing Director, Emcure Pharmaceuticals, said, “Emcure delivered a very strong performance in Q4 with all our businesses segments contributing to growth. Over the past year we have effectively executed our strategies across both Domestic and International markets. On the Domestic side we have expanded our covered market and built a strong product pipeline of upcoming launches. In the International markets we are seeing approvals for our differentiated product offerings. Moving forward, while we continue to drive growth, our key priorities will be improving margins through new product launches and operating efficiencies.”

Result PDF

Pharmaceuticals company Emcure Pharmaceuticals announced Q3FY25 results

  • Revenue: Rs 1,963 crore compared to Rs 1,668 crore during Q3FY24, change 17.7%.
  • EBITDA: Rs 362 crore compared to Rs 294 crore during Q3FY24, change 23.2%.
  • EBITDA Margins: 18.4% for Q3FY25.
  • PAT: Rs 156 crore compared to Rs 120 crore during Q3FY24, change 30.3%.
  • PAT margin: 8.0% for Q3FY25.

Satish Mehta, CEO and Managing Director, Emcure Pharmaceuticals, said: “Emcure witnessed a strong performance in Q3. Our International business is seeing strong performance on back of our differentiated product portolio. On the domestic side, our focus is on expanding our covered market through differentiated product launches and driving synergies from the in-licensed Sanofi portolio. Moving forward, we aim to enhance our organic growth and margins through new product launches and operating efficiencies.”

Result PDF

Pharmaceuticals company Emcure Pharmaceuticals announced Q2FY25 results

  • Revenue from operations at Rs 2,002 crore, up 20.4% YoY and 10.3% QoQ.
  • EBITDA margins at 20.8% with EBITDA up 26.1% YoY and 15.8% QoQ.
  • PAT at 202 crore, up 38.2% YoY with PAT margins at 10.1%.
  • Domestic business sales at 933 crore, up 15.4% YoY.
  • International business sales at 1,069 crore, up 25.0% YoY.

Satish Mehta, CEO and Managing Director, Emcure Pharmaceuticals, said: “Emcure witnessed a strong performance in Q2. We have made significant investments in both our International and Domestic businesses over the past 2 years and the benefits of these efforts are starting to particularly reflect in the growth of our International business. Our recent inorganic additions – Sanofi partnership in India and Mantra acquisition in Canada – are now fully integrated and our focus is now on deriving both revenue and operational synergies. Moving forward, we aim to enhance the margins by leveraging operating efficiencies, while continuing to drive strong growth in both Indian and International markets through new product launches and market share gains.”

Result PDF

Trending News

IQVIA: Indian Pharma Market grows 13% YoY to ₹24,827 cr in August; Chronic segment surges 16%Show Code

As per IQVIA, Indian Pharma Market grew at 13% YoY to ₹ 24,827 crore in August 2026. On the MAT (trailing 12 months) basis, IPM witnessed a growth of 12.3% to ₹ 271,284 crore. 

Published on 11-Sep-2026 09:12

India CV Growth Outlook Hiked to 10-15% for FY27 as Q1 and August Sales Surge Past Estimates

According to media sources, India’s commercial vehicle (CV) industry has sharply upgraded its FY27 growth outlook after demand in the first five months significantly exceeded expectations. 

Published on 11-Sep-2026 09:11

UPI Merchant Levy of 40 bps in the Works; Issuing Banks to Get Max Share; Free for Small Retailers

As per media sources, a ~40 bps MDR on select UPI merchant transactions is being worked out, with issuing banks expected to receive the largest share

Published on 11-Sep-2026 09:10

HDFC Bank wins all 7 Credit Suisse AT1 bond cases in Bahrain

As per media sources, HDFC Bank has won all seven cases filed against it in Bahrain by investors in Credit Suisse AT1 bonds, providing relief from allegations of mis-selling. 

Published on 11-Sep-2026 09:09

Neogen Chemicals launches QIP with ₹2,189.73/share floor price

Neogen Chemicals has invited bids from eligible qualified institutional buyers under its QIP, with the floor price set at ₹2,189.73/share. 

Published on 11-Sep-2026 09:08

KIMS Hospitals to operate 183-bed Trust Hospital in Kakinada

KIMS Hospitals has entered into an Operation and Management (O&M) Agreement with Sarvottam Health Care Pvt Ltd to become the exclusive operator of Trust Multispeciality Hospital in Kakinada, Andhra Pradesh

Published on 11-Sep-2026 09:07

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Get it on google Play Store Download on the App Store
market app